Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage
- 1 May 2022
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , 1046-1053
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancerOncotarget, 2017
- Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancerCancer Science, 2017
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialThe Lancet, 2017
- The Cobas ® EGFR Mutation Test v2 AssayFuture Oncology, 2016
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial NeoplasiaGastroenterology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by Computed TomographySurgical Endoscopy, 2005
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 2004
- Digital PCRProceedings of the National Academy of Sciences, 1999
- Neoplastic Characteristics of the DNA Found in the Plasma of Cancer PatientsOncology, 1989